Cystic Fibrosis (CF)

Rare Diseases
3
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sionna Therapeutics
2 programs
1
1
SION-719Phase 21 trial
SION-451Phase 11 trial
Active Trials
NCT07035990RecruitingEst. Jun 2026
NCT07108153RecruitingEst. Jul 2026
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
MP-376Phase 21 trial
Active Trials
NCT00677365Completed151Est. Jun 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sionna TherapeuticsSION-719
AmgenMP-376
Sionna TherapeuticsSION-451

Clinical Trials (3)

Total enrollment: 151 patients across 3 trials

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

Start: Nov 2025Est. completion: Jul 2026
Phase 2Recruiting

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Start: Jun 2008Est. completion: Jun 2009151 patients
Phase 2Completed

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

Start: Jul 2025Est. completion: Jun 2026
Phase 1Recruiting

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 151 patients
2 companies competing in this space